Visual testing on iPad convenient and easy

Article

An iPad-based letter contrast sensitivity test could be a quick, easy, and convenient alternative to more traditional testing measures. This new tool, developed by Ridgevue Vision, has the advantage of being interactive as well.

 

Seattle-An iPad-based letter contrast sensitivity test could be a quick, easy, and convenient alternative to more traditional testing measures. This new tool, developed by Ridgevue Vision, has the advantage of being interactive as well, explained Mark A. Bullimore, MCOptom, PhD, FAAO, a professor at The Ohio State University College of Optometry.

Dr. Bullimore and colleagues conducted an evaluation of the iPad test, and discussed the results of his study at the annual meeting of the American Academy of Optometry.

The iPad test presents two letters per page and in 0.1 log unit steps, and the researchers compared it with two of the standard tests, the Freiburg and the Pelli-Robson. Their cohort included 20 individuals with normal sight and 20 with low vision.

“The repeatability was comparable with the other tests,” Dr. Bullimore pointed out. “For normal-sighted subjects, our values were comparable with another computer-based test, the Freiberg test.”

However, the Pelli-Robson test gave significantly lower values. Persons with low vision had slightly lower repeatability (iPad = ±0.24, Pelli-Robson =  ±0.23, Freiburg = ±0.21).

Unlike other tests, this one does not require external lighting and runs on the iPad without need for special software or calibration. “You can just download it from the iTunes store,” said Dr. Bullimore.

An un-validated student version with one letter per contrast level is also available from the iTunes store.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.